Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
American Association of Individual Investors1d
Which Is a Better Investment, Jazz Pharmaceuticals plc or Johnson & Johnson Stock?
Learn more about whether Jazz Pharmaceuticals plc or Johnson & Johnson is a better investment based on AAII's A+ Investor ...
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Rhythm Pharmaceuticals (RYTM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and ...
Soap Central1d
Rhythm + Flow Italy Season 2 Episode 4 recap: Rappers battle it out in a cypher, the first contestants are eliminated
On March 31, 2025, the second season of Netflix's Rhythm + Flow Italy premiered, bringing new talent and huge stakes to the ...
Soap Central1d
Rhythm + Flow Italy Season 2 Episode 3: High-stake auditions push artists to their limits
Netflix released the all-new season 2 of Rhythm + Flow Italy, and its episode 3 increased the stakes for competitors due to ...
Game Rant2d
New Rhythm Heaven Game Revealed for Switch
A new game in the Rhythm Heaven series is finally on its way to the Nintendo Switch, marking the first entry in over a decade.
Explore more
Nintendo Insider3d
Don’t Miss A Beat In Rhythm Paradise Groove On Nintendo Switch
Nintendo has announced that Rhythm Paradise Groove - or Rhythm Heaven Groove as it is called in North America - is in ...
Stocktwits on MSN4d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
US FDA declines to approve Milestone's heart rhythm nasal spray
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...